Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address unmet medical needs in oncology. The company focuses on developing differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Actinium Pharmaceuticals, Inc. does
In the company’s own words
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address unmet medical needs in oncology. The company focuses on developing differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies by combining deep understanding of tumor biology and translational medicine with expertise in radiochemistry. More information is available at www.actiniumpharma.com.
The company's pipeline spans multiple therapeutic areas. In solid tumors, Actinium is advancing ATNM-400, a first-in-class Ac-225 antibody radioconjugate targeting a novel non-PSMA antigen with demonstrated preclinical activity across metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer. Actimab-A is being developed as an immunomodulatory therapy targeting myeloid-derived suppressor cells to enhance checkpoint inhibitor efficacy in solid tumors including head and neck squamous cell carcinoma, glioblastoma, and colorectal cancer.
The hematology franchise includes Actimab-A for acute myeloid leukemia and myelodysplastic syndrome, developed in partnership with the National Cancer Institute, as well as Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents for bone marrow transplant and cell and gene therapies. Both Actimab-A and Iomab-B are Phase 2/3-ready assets supported by extensive clinical validation across more than 15 trials treating over 500 patients.
Actinium has built vertically integrated capabilities spanning the radiopharmaceutical value chain, including proprietary cyclotron-based Ac-225 production technology, an end-to-end supply chain with relationships at approximately 50 leading cancer centers, and a cGMP manufacturing facility expected to be operational in the second half of 2026. The company maintains a strong intellectual property portfolio comprising approximately 250 issued patents and pending applications, including composition of matter patents and proprietary production technology patents extending into 2037 and 2038.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1388320
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Actinium Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Actinium Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Actinium Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Actinium Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Actinium Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”